A Pilot study to evaluate the Efficacy and Safety of GFT505 orally administered once daily (30 mg) for 28 days in atherogenic dyslipidaemic patients with abdominal obesity. A double blind, placebo-controlled and randomized study.
Read time: 1 mins
Last updated:28th Aug 2007
To evaluate the efficacy of GFT505 30 mg in reducing serum TG and increasing HDL-C levels compared with placebo in atherogenic dyslipidaemic patients with abdominal obesity. To assess the tolerability and safety of once-a-day administrations of oral doses of GFT505 during 28 days.
|Study start date||2007-08-28|